The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
“In the pharmaceutical drug development community, this is what you dream about.”
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
The Miller School of Medicine is Studying CBD + Psilocybin for Treating Traumatic Brain Injury and PTSD
The University of Miami medical school study is funded by a $1.624 million grant from Tassili Life Sciences.
This new knowledge provides more options for developing psychedelics into therapeutic drug formulations.
Anorexia has phenomenological parallels to anxiety and addiction, both of which have been shown to improve with psilocybin-assisted interventions.
Psilacetin is less expensive and easier to make than psilocybin.
The answer is yes and no. It's a matter of perspective.